Trial register facet
Trial records in type 2 diabetes mellitus — page 7
247 records bearing on type 2 diabetes mellitus.
Showing 0 records on this page
Records
247 documents · page 7 of 11
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| HARMONY-OUTCOMES-ADHERENCEprogramme record | Dulaglutide | Phase 3 | Reported | Observational | — | 2018 | Very low |
| SUSTAIN-1 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 388 | 2017 | High |
| EXSCEL | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 14,752 | 2017 | High |
| SUSTAIN-1-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| EXSCEL-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| EXSCEL-QOLprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| EXSCEL-BODY-COMPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-BODY-COMPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2017 | Very low |
| SUSTAIN-6 | Semaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 3,297 | 2016 | High |
| LEADER | Liraglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,340 | 2016 | High |
| SUSTAIN-6-BODY-COMPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| LEADER-OLEprogramme record | Liraglutide | Phase 3 | Reported | Single-arm open-label | — | 2016 | Very low |
| SUSTAIN-6-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| LEADER-ELDERLYprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| SUSTAIN-6-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| LEADER-BIOMARKERprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| SUSTAIN-6-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| LEADER-QOLprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| ELIXA | Lixisenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 6,068 | 2015 | High |
| ELIXA-DDIprogramme record | Lixisenatide | Phase 1 | Reported | Randomised crossover | — | 2015 | Very low |
| ELIXA-HEPATIC-IMPprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2015 | Very low |
page 7 of 11